Neuraxis (NRXS) Stock Price

Neuraxis Price

NYSE·CLOSED
6.15USD-0.12 (-1.93 %)
Market closed

Over the last 4 years Neuraxis grew revenue by 8.6% annually, reaching 2.69 M USD. For Neuraxis, the net margin of -314.7% is down versus -223.8% a few years ago. The consensus 12-month price target for Neuraxis is 7.14 USD, about 16.1% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 166% above its 52-week low.

Neuraxis stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Neuraxis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Neuraxis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Neuraxis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Neuraxis Stock Price History
DateNeuraxis Price
8/21/20266.15 USD
8/20/20266.27 USD
8/19/20266.28 USD
8/18/20266.31 USD
8/17/20266.28 USD
8/14/20266.30 USD
8/13/20266.28 USD
8/12/20266.46 USD
8/10/20266.87 USD
8/7/20267.09 USD
8/6/20266.93 USD
8/5/20266.86 USD
8/4/20266.81 USD
8/3/20266.59 USD
7/31/20266.25 USD
7/30/20266.28 USD
7/29/20266.07 USD
7/27/20266.63 USD
7/23/20267.01 USD
7/22/20266.87 USD
7/21/20267.01 USD
7/20/20266.86 USD
7/17/20266.75 USD
7/16/20266.78 USD
7/15/20266.98 USD
7/14/20267.15 USD
7/13/20267.28 USD
7/10/20267.14 USD
7/9/20267.21 USD
7/8/20267.09 USD
7/7/20267.13 USD
7/6/20267.16 USD
7/2/20267.06 USD
7/1/20267.08 USD
6/30/20267.31 USD
6/29/20267.14 USD
6/26/20267.27 USD
6/25/20266.91 USD
6/24/20266.80 USD
6/23/20267.00 USD
6/22/20267.05 USD
6/18/20267.15 USD
6/17/20266.71 USD
6/16/20266.71 USD
6/15/20266.80 USD
6/12/20266.70 USD
6/11/20266.89 USD
6/10/20266.80 USD
6/9/20266.80 USD
6/8/20266.67 USD
6/5/20266.84 USD
6/4/20267.27 USD
6/3/20267.07 USD
6/2/20267.01 USD
6/1/20267.34 USD
5/29/20267.41 USD
5/28/20267.29 USD
5/27/20267.45 USD
5/26/20267.00 USD
5/22/20267.38 USD
5/21/20267.43 USD
5/20/20267.25 USD
5/19/20267.25 USD
5/18/20267.41 USD
5/15/20267.87 USD
5/14/20267.89 USD
5/13/20267.91 USD
5/12/20268.27 USD
5/11/20268.15 USD
5/8/20268.20 USD
5/7/20268.80 USD
5/6/20268.81 USD
5/5/20268.69 USD
5/4/20268.30 USD
5/1/20268.08 USD
4/30/20267.45 USD
4/29/20267.44 USD
4/28/20267.61 USD
4/27/20268.13 USD
4/24/20267.86 USD
4/23/20267.40 USD
4/22/20267.51 USD
4/21/20267.28 USD
4/20/20267.00 USD
4/17/20267.22 USD
4/16/20267.36 USD
4/15/20267.00 USD
4/14/20267.18 USD
4/13/20266.99 USD
4/10/20266.84 USD
4/9/20267.25 USD
4/8/20267.10 USD
4/7/20267.34 USD
4/6/20267.41 USD
4/2/20267.25 USD
4/1/20267.18 USD
3/31/20267.40 USD
3/30/20266.61 USD
3/27/20266.90 USD
3/26/20267.00 USD
3/25/20267.51 USD
3/24/20267.05 USD
3/23/20267.31 USD
3/20/20267.62 USD
3/19/20267.16 USD
3/18/20266.99 USD
3/17/20267.21 USD
3/16/20267.05 USD
3/13/20266.86 USD
3/12/20266.48 USD
3/11/20266.45 USD
3/10/20266.31 USD
3/9/20265.75 USD
3/6/20265.71 USD
3/5/20265.88 USD
3/4/20265.81 USD
3/3/20265.89 USD
3/2/20266.30 USD
2/27/20266.00 USD
2/26/20265.69 USD
2/25/20265.28 USD
2/24/20265.01 USD
2/23/20264.75 USD
2/20/20265.53 USD
2/19/20265.35 USD
2/18/20265.36 USD
2/17/20265.39 USD
2/13/20264.91 USD
2/12/20264.85 USD
2/11/20264.65 USD
2/10/20264.62 USD
2/9/20264.36 USD
2/6/20264.35 USD
2/5/20264.35 USD
2/4/20264.35 USD
2/3/20264.21 USD
2/2/20264.42 USD
1/30/20264.23 USD
1/29/20264.65 USD
1/28/20264.66 USD
1/27/20264.57 USD
1/26/20264.68 USD
1/23/20264.86 USD
1/22/20264.63 USD
1/21/20264.91 USD
1/20/20264.65 USD
1/16/20264.57 USD
1/15/20264.60 USD
1/14/20264.74 USD
1/13/20264.92 USD
1/12/20265.15 USD
1/9/20264.86 USD
1/8/20264.63 USD
1/7/20264.44 USD
1/6/20264.46 USD
1/5/20264.41 USD
1/2/20264.46 USD
12/31/20254.54 USD
12/30/20254.51 USD
12/29/20254.20 USD
12/26/20253.92 USD
12/24/20253.82 USD
12/23/20253.48 USD
12/22/20254.03 USD
12/19/20253.22 USD
12/18/20252.88 USD
12/17/20252.76 USD
12/16/20252.70 USD
12/15/20252.65 USD
12/12/20252.65 USD
12/11/20252.63 USD
12/10/20252.76 USD
12/9/20252.70 USD
12/8/20252.63 USD
12/5/20252.67 USD
12/4/20252.71 USD
12/3/20252.78 USD
12/2/20252.68 USD
12/1/20252.67 USD
11/28/20252.78 USD
11/26/20252.67 USD
11/25/20252.65 USD
11/24/20252.58 USD
11/21/20252.62 USD
11/20/20252.51 USD
11/19/20252.54 USD
11/18/20252.40 USD
11/17/20252.31 USD
11/14/20252.34 USD
11/13/20252.35 USD
11/12/20252.60 USD
11/11/20252.41 USD
11/10/20252.56 USD
11/7/20252.54 USD
11/6/20252.53 USD
11/5/20252.54 USD
11/4/20252.54 USD
11/3/20252.68 USD
10/31/20252.72 USD
10/30/20252.79 USD
10/29/20253.02 USD
10/28/20253.02 USD
10/27/20253.11 USD
10/24/20253.49 USD
10/23/20253.82 USD
10/22/20253.79 USD
10/21/20253.70 USD
10/20/20253.68 USD
10/17/20253.03 USD
10/16/20253.14 USD
10/15/20253.33 USD
10/14/20253.03 USD
10/13/20253.07 USD
10/10/20252.98 USD
10/9/20253.04 USD
10/8/20253.13 USD
10/7/20253.01 USD
10/6/20253.15 USD
10/3/20253.18 USD
10/2/20253.19 USD
10/1/20253.11 USD
9/30/20253.08 USD
9/29/20253.11 USD
9/26/20252.99 USD
9/25/20252.75 USD
9/24/20252.69 USD
9/23/20252.68 USD
9/22/20252.69 USD
9/19/20252.54 USD
9/18/20252.61 USD
9/17/20252.56 USD
9/16/20252.43 USD
9/15/20252.34 USD
9/12/20252.42 USD
9/11/20252.42 USD
9/10/20252.44 USD
9/9/20252.45 USD
9/8/20252.42 USD
9/5/20252.43 USD
9/4/20252.46 USD
9/3/20252.54 USD
9/2/20252.63 USD
8/29/20252.54 USD
8/28/20252.48 USD
8/27/20252.42 USD
8/26/20252.45 USD
8/25/20252.54 USD
Access this data via the Eulerpool API
Get Free API Key

Neuraxis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.93 M USD
-4.12 M USD
-4.32 M USD
Jan 1, 2021
2.72 M USD
-2.97 M USD
-3.78 M USD
Jan 1, 2022
2.68 M USD
-3.37 M USD
-5.54 M USD
Jan 1, 2023
2.46 M USD
-6.66 M USD
-14.63 M USD
Jan 1, 2024
2.69 M USD
-7.16 M USD
-8.45 M USD
Jan 1, 2025 (e)
3.52 M USD
-7.69 M USD
-10.37 M USD
Jan 1, 2026 (e)
8.67 M USD
-3.82 M USD
-5.92 M USD
Jan 1, 2027 (e)
19.07 M USD
-1.94 M USD
-1.52 M USD

Neuraxis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 24, 2026, 12:35 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
202020212022202320242025e2026e2027e
1.002.002.002.002.003.008.0019.00
–100.00–––50.00166.67137.50
100.00100.00100.00100.00100.00100.00100.00100.00
1.002.002.002.002.003.008.0019.00
-4.00-2.00-3.00-6.00-7.00-7.00-3.00-1.00
-400.00-100.00-150.00-300.00-350.00-233.33-37.50-5.26
-4.00-3.00-5.00-14.00-8.00-10.00-5.00-1.00
–-25.0066.67180.00-42.8625.00-50.00-80.00
6.116.116.113.256.926.926.926.92
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Neuraxis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Neuraxis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Neuraxis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Neuraxis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Neuraxis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Neuraxis stock margins

The Neuraxis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neuraxis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neuraxis.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
75.13 %
-213.47 %
-223.83 %
Jan 1, 2021
82.72 %
-109.19 %
-138.97 %
Jan 1, 2022
89.18 %
-125.75 %
-206.72 %
Jan 1, 2023
87.67 %
-270.90 %
-594.56 %
Jan 1, 2024
86.52 %
-266.46 %
-314.71 %
Jan 1, 2025 (e)
86.52 %
-218.59 %
-294.72 %
Jan 1, 2026 (e)
86.52 %
-44.06 %
-68.29 %
Jan 1, 2027 (e)
86.52 %
-10.16 %
-7.97 %

Neuraxis Stock Revenue, EBIT, Earnings per Share

The Neuraxis earnings per share therefore indicates how much revenue Neuraxis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.32 USD
-0.67 USD
-0.71 USD
Jan 1, 2021
0.45 USD
-0.49 USD
-0.62 USD
Jan 1, 2022
0.44 USD
-0.55 USD
-0.91 USD
Jan 1, 2023
0.76 USD
-2.05 USD
-4.50 USD
Jan 1, 2024
0.39 USD
-1.03 USD
-1.22 USD
Jan 1, 2025 (e)
0.33 USD
-1.11 USD
-0.97 USD
Jan 1, 2026 (e)
0.81 USD
-0.55 USD
-0.56 USD
Jan 1, 2027 (e)
1.79 USD
-0.28 USD
-0.14 USD

Neuraxis business model & stock analysis

Neuraxis Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Neuraxis historical P/E ratio, EBIT multiple, and P/S ratio

Neuraxis annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Neuraxis shares outstanding

The number of shares of Neuraxis was 6.92 M in 2025. This indicates how many shares Neuraxis is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
6.11 M Stocks
Jan 1, 2021
6.11 M Stocks
Jan 1, 2022
6.11 M Stocks
Jan 1, 2023
3.25 M Stocks
Jan 1, 2024
6.92 M Stocks
Jan 1, 2025 (e)
6.92 M Stocks
Jan 1, 2026 (e)
6.92 M Stocks
Jan 1, 2027 (e)
6.92 M Stocks

Current Neuraxis forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
9.80 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
7.14
Last Price
6.15
Currency
USD
12M Return Potential
16.10 %
LTM Return
0 %

Neuraxis Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/12/2026-0.33USD-2.04 MUSD-2026 Q2
5/12/2026-0.19USD-1.48 MUSD-2026 Q1
3/20/2026-0.22USD-867,000.00USD-2025 Q4
11/18/2024-USD-3.20 MUSD-2024 Q3

Neuraxis shareholder structure

% Name
10.62462%
Hannasch (Brian)
Hannasch (Brian)
7.44448%
Brown (Christopher Robin)
Brown (Christopher Robin)
2.79286%
AIGH Capital Management, LLC.
AIGH Capital Management, LLC.
1.16454%
Apis Capital Advisors LLC
Apis Capital Advisors LLC
1.09602%
Parsons Capital Management, Inc.
Parsons Capital Management, Inc.
0.96300%
Worth Venture Partners, LLC
Worth Venture Partners, LLC

Neuraxis Executives and Management Board

9 members · avg. age 55 · 22 % women

TH

Mr. Timothy Henrichs (52)

Chief Financial Officer · since 2023

638,521.00 USD

Management

BC

Mr. Brian Carrico (43)

President, Chief Executive Officer, Director

578,376.00 USD
AM

Dr. Adrian Miranda (55)

Chief Medical Officer, Senior Vice President - Science and Technology

382,445.00 USD
TC

Dr. Thomas Carrico (68)

Chief Regulatory Officer, Compliance Officer and Privacy Officer

368,914.00 USD

Board of Directors

BW

Mr. Bradley Watkins (50)

Independent Chairman of the Board · since 2023

110,000.00 USD
BK

Ms. Beth Keyser (56)

Independent Director

110,000.00 USD
KF

Ms. Kristin Ferge (51)

Independent Director

90,110.00 USD
CB

Dr. Christopher Brown (71)

Director

–
GA

Dr. Gilad Aharon (51)

Independent Director

–

Frequently asked questions about Neuraxis

Analysts currently set an average price target of 7.14 USD for the Neuraxis stock (median: 7.14 USD), implying +16.1 % versus the latest price. The consensus is based on 8 analyst ratings.

Neuraxis Analyst Price Targets 2026

8 analysts currently rate the Neuraxis stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neuraxis to generate revenue of 8.67 M USD and earnings per share of -0.86 USD.

Neuraxis Analyst Price Targets 2026

Converted at the current exchange rate, the Neuraxis share trades at 5.27 EUR (6.15 USD).

No history available for Neuraxis.

The expected revenue of Neuraxis is 8.67 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Neuraxis is -5.92 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Neuraxis is currently -7.19. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neuraxis stock.

The price-to-sales ratio (P/S) of Neuraxis is currently 4.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neuraxis stock.

The Eulerpool Quality Score for Neuraxis is 2/10.

The ISIN of Neuraxis is US64134X2018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Neuraxis is NRXS. The ticker symbol is used to trade Neuraxis shares on the stock exchange.

Neuraxis paid dividends every year for the past 0 years.

Neuraxis is assigned to the 'Health' sector.

The dividends of Neuraxis are distributed in USD.

All fundamentals and in-depth analysis of Neuraxis

Our stock analysis for Neuraxis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuraxis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Neuraxis Stock
Neuraxis Revenue→
Neuraxis Stock
Neuraxis Net Income→
Neuraxis Stock
Neuraxis P/E→
Neuraxis Stock
Neuraxis P/S→
Neuraxis Stock
Neuraxis EBIT→
Neuraxis Stock
Neuraxis Dividend→
Neuraxis Stock
Neuraxis Directors Dealings→
Neuraxis Stock
Neuraxis Stocks→
Neuraxis Stock
Neuraxis Market capitalization→
Neuraxis Stock
Neuraxis Debt→
Neuraxis Stock
Neuraxis Liabilities→
Neuraxis Stock
Neuraxis Equity→
Neuraxis Stock
Neuraxis AAQS→
Neuraxis Stock
Neuraxis Employees→
Neuraxis Stock
Neuraxis ROE→
Neuraxis Stock
Neuraxis ROA→
Neuraxis Stock
Neuraxis ROCE→
Neuraxis Stock
Neuraxis News→
Neuraxis Stock
Neuraxis Analyst Price Targets→

Health Stocks

Neuren PharmaceuticalsNeuphoria TherapeuticsNeurizon TherapeuticsNeuPath HealthNeuro-HitechNeumora TherapeuticsNeurocrine BiosciencesNeuland LaboratoriesNeurogeneNeucaNeuroneticsNetraMark HoldingsAll Stocks A–Z →